Renin inhibitors and cardiovascular and renal protection: an endless quest? (Q37990796)

26 August 2017

title

Renin inhibitors and cardiovascular and renal protection: an endless quest? (English)

1 reference

26 August 2017

1 reference

Michel Azizi

1

1 reference

26 August 2017

Joël Ménard

series ordinal

2

1 reference

26 August 2017

publication date

1 April 2013

1 reference

Cardiovascular Drugs and Therapy

26 August 2017

published in

1 reference

26 August 2017

volume

27

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

145-153

1 reference

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Telmisartan to prevent recurrent stroke and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Renin inhibition: what are the therapeutic opportunities?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Clinical Pharmacokinetics and Efficacy of Renin Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Structure-based design of aliskiren, a novel orally effective renin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Clinical pharmacokinetics and pharmacodynamics of aliskiren

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Renin inhibition with aliskiren: where are we now, and where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Aliskiren accumulates in Renin secretory granules and binds plasma prorenin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

The continuing saga of the AT2 receptor: a case of the good, the bad, and the innocuous.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Angiotensin I converting enzyme and the changes in our concepts through the years. Lewis K. Dahl memorial lecture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Plasma bradykinin in angio-oedema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Renin inhibition with aliskiren

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Aliskiren: the first renin inhibitor for clinical treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Blood pressure lowering efficacy of renin inhibitors for primary hypertension: a Cochrane systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Aliskiren vs. angiotensin receptor blockers in hypertension: meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

A systematic review and meta-analysis of aliskiren and angiotension receptor blockers in the management of essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Direct Renin inhibition with aliskiren in obese patients with arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Direct renin inhibition and the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Effects of combined administration of ACE inhibitor and angiotensin II receptor antagonist are prevented by a high NaCl intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Haemodynamic effects of dual blockade of the renin-angiotensin system in spontaneously hypertensive rats: influence of salt

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Effect of direct renin inhibition on renal hemodynamic function, arterial stiffness, and endothelial function in humans with uncomplicated type 1 diabetes: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Surrogate end points for clinical trials of kidney disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Renal dysfunction complicating the treatment of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Effects of intensive blood-pressure control in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Managing cardiovascular and renal risk: the potential of direct renin inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Renin is not synthesized by cardiac and extrarenal vascular tissues. A review of experimental evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Renal vascular responses to renin inhibition with zankiren in men*

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Dual inhibition of the renin system by aliskiren and valsartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6380-6

10.1007/S10557-012-6380-6

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference